PRPO - Precipio, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
1.9900
-0.0400 (-1.97%)
As of 12:35PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close2.0300
Open2.0600
Bid1.9900 x 3000
Ask2.0000 x 1200
Day's Range1.9150 - 2.0600
52 Week Range1.6500 - 10.8000
Volume52,525
Avg. Volume531,060
Market Cap14.786M
Beta (3Y Monthly)3.62
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Benzinga

    A Lack Of Momentum Leads To A Lesson In Patience

    Despite early hopes to the contrary, it looks as though September is going to end up as a relatively flat month for my trading account. Although there was some strong action coming out of August that carried ...

  • Benzinga

    A Look At Benzinga Pro's Most-Searched Tickers For September 27, 2019

    This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Micron Technology, Inc.  (NASDAQ: MU ) shares ...

  • Precipio News: PRPO Stock Surges on Deal With Hospitals in Egypt
    InvestorPlace

    Precipio News: PRPO Stock Surges on Deal With Hospitals in Egypt

    Precipio news about the company signing a deal with hospitals in Egypt.Source: Shutterstock Precipio (NASDAQ:PRPO) says that this deal has it signing its first major international services contract. This contract is with a health care management group that serves multiple hospitals in Cairo, Egypt.The Precipio news will have the cancer diagnostics company offering its pathology diagnostic services to these hospitals. It will also be providing them with access to its proprietary technologies that it develops.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThis Precipio news also includes the company's expectations from the deal. That includes the company expecting "significant first year revenues" from its ICE-COLD PCR technology and HemeScreen for hematologic molecular testing. Precipio says that it will be expecting these tests to become available in Egypt by the end of the second quarter.Precipio says that it is expecting other benefits from this deal as well. Among these is an early estimate that H2-2019 gross margin will improve by 20 points to 25 points. It is also expecting to see cash burn decrease. * 7 A-Rated Stocks That Are Under $10 "I am delighted to see the benefits of our international efforts beginning to capitalize on Precipio's platform and technologies and deliver the highest level of expertise to patients worldwide,'" Ilan Danieli, CEO of PRPO, said in the Precipio news release. "The international segment of our business is going to be a valuable contributor to our revenues, margins and cash flow in the coming quarters."PRPO stock was up 4% as of noon Monday. More From InvestorPlace * 7 A-Rated Stocks That Are Under $10 * 7 U.S. Shale Oil Stocks to Buy as Prices Rise * 10 Stocks to Sell Before They Give Back 2019 Gains * 10 Oversold Stocks to Run From As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post Precipio News: PRPO Stock Surges on Deal With Hospitals in Egypt appeared first on InvestorPlace.